Read by QxMD icon Read


Kiyohiro Sakai, Masayuki Takeda, Hidetoshi Hayashi, Kaoru Tanaka, Takeshi Okuda, Amami Kato, Yasumasa Nishimura, Tetsuya Mitsudomi, Atsuko Koyama, Kazuhiko Nakagawa
INTRODUCTION: The concept of "oligometastasis" has emerged as a basis on which to identify patients with stage IV non-small cell lung cancer (NSCLC) who might be most amenable to curative treatment. Limited data have been available regarding the survival of patients with node-negative oligometastatic NSCLC. PATIENTS AND METHODS: Consecutive patients with advanced NSCLC who attended Kindai University Hospital between January 2007 and January 2016 were recruited to this retrospective study...
September 12, 2016: Thoracic Cancer
Zhenhai Lu, Jianhong Peng, Zhiqiang Wang, Zhizhong Pan, Yunfei Yuan, Desen Wan, Binkui Li
Oligometastasis is defined as a transitional state between localized and widespread systemic metastatic cancers. In colorectal cancer, the prognostic factors and prognostic value of preoperative serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for patients with colorectal liver oligometastases (CLOM) undergoing hepatic resection have not been well explored. Therefore, the present study included 141 patients with CLOM (≤5 liver metastases) who underwent R0 resection from 2005 to 2012...
November 2016: Medical Oncology
T R Merino Lara, J Helou, I Poon, A Sahgal, H T Chung, W Chu, H Soliman, S Verma, P Cheema, S Cheng, S Khanna, D Erler, L Zhang, P Cheung
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
K Jingu, Y Matsuo, H Onishi, T Yamamoto, M Aoki, Y Murakami, H Yamashita, H Kakuhara, K Nemoto, T Sakayauchi, M Okamoto, Y Niibe, K Ogawa
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
R B Goody, T Panzarella, P E Lindsay, D M Paravasthu, A M Brade, L A Dawson, P Chung, A Bezjak, J Brierley, J J Kim, J G Ringash, A Sun, M E Giuliani, A J Hope, S Gill, R Wong
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Johnny Kao, Jonathan Timmins, Junko Ozao-Choy, Stuart Packer
There is considerable interest in deploying stereotactic body radiotherapy in combination with immune therapy for patients with extracranial oligometastases. In addition to angiogenesis inhibition, sunitinib appears to mediate antitumor immunity through effects on circulating monocytic cells. The current study investigated the effects of combined sunitinib and stereotactic radiotherapy on hematopoiesis. As part of a phase I/II clinical trial utilizing concurrent sunitinib (25-50 mg on days 1-28) and image-guided radiation therapy (40-50 Gy in 10 fractions starting on days 8-19) for patients with metastatic cancer, the complete blood count, platelet count and automatic differential were performed pretreatment and on days 8 and 19...
September 2016: Oncology Letters
James M Franklin, Ricky A Sharma, Adrian L Harris, Fergus V Gleeson
With the advent of novel treatment strategies to help widen the therapeutic window for patients with oligometastatic cancer, improved biomarkers are needed to reliably define patients who can benefit from these treatments. Multimodal imaging is one such option and should be optimised to comprehensively assess metastatic sites, disease burden, and response to neoadjuvant treatment in each disease setting. These features will probably remain important prognostic biomarkers, and are crucial in planning multidisciplinary treatment...
September 2016: Lancet Oncology
Axel Heidenreich, Judd W Moul, Shahrokh Shariat, R Jeffrey Karnes
PURPOSE OF REVIEW: Oligometastatic prostate cancer (PCA) has increasingly been detected in the era of modern imaging studies such as choline-specific and prostate-specific membrane antigen (PSMA)-positron emission tomography and X-ray computed tomography (PET/CT). Recent evidence suggests that durable control is attainable with local treatment modalities such as salvage metastasectomy or stereotactic radiation therapy targeting oligometastases, either with or without the use of systemic therapy...
November 2016: Current Opinion in Urology
Jung Won Choi, Doo-Sik Kong, Ho Jun Seol, Do-Hyun Nam, Kwai Han Yoo, Jong-Mu Sun, Jin-Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jung-Il Lee
OBJECTIVE: Crizotinib is a novel targeted anticancer agent for non-small cell lung cancer (NSCLC). In this study, we report our clinical outcomes from gamma knife radiosurgery (GKS) for brain metastasis (BM) under crizotinib treatment in NSCLC patients. METHODS: We performed a retrospective review of 29 patients who underwent a total of 51 GKS procedures for BM while continuing on crizotinib. We compared two groups based on the number of BM, the oligometastases (≤5) and polymetastases (>5) groups...
August 23, 2016: World Neurosurgery
Yuzuru Niibe, Tetsuo Nishimura, Tetsuya Inoue, Katsuyuki Karasawa, Yoshiyuki Shioyama, Keiichi Jingu, Hiroki Shirato
BACKGROUND: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT). METHODS: Patients treated with SRS or SRT for brain-only NSCLC oligometastases in 6 high-volume institutions in Japan between 1996 and 2008 were reviewed. Eligible patients met 1), 2), and 4) or 1), 3), and 4) of the following: 1) NSCLC with 1 to 4 brain metastases on magnetic resonance imaging (MRI) treated with SRS or SRT; 2) control of the primary lesions (thorax) at the time of SRS or SRT for brain metastases (patients meeting this criterion formed the oligo-recurrence group); 3) with SRS or SRT for brain metastases, concomitant treatment for active primary lesions (thorax) with curative surgery or curative stereotactic body radiotherapy (SBRT), or curative chemoradiotherapy (sync-oligometastases group); and 4) Karnofsky performance status (KPS) ≥70...
August 19, 2016: BMC Cancer
Swetha Sridharan, Allison Steigler, Nigel A Spry, David Joseph, David S Lamb, John H Matthews, Chris Atkinson, Keen-Hun Tai, Gillian Duchesne, David Christie, John Attia, Elizabeth G Holliday, James W Denham
BACKGROUND: It remains unclear whether eradication of oligometastases by stereotactic body radiation therapy or other means will result in cure or prolongation of survival in some cases, or merely provide palliation. We address this issue with prospectively collected progression and treatment data from the TROG 03.04 RADAR randomised controlled trial for men with locally advanced prostate cancer (PC). METHODS: Three Fine and Gray competing risk survival models with time-dependent covariates were used to determine whether metastatic progression status at first diagnosis of bony metastases, i...
August 12, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Juliette Thariat, Stéphane Vignot
Oligometastic progression (or solitary metastases) can justify ablative treatment for metastatic treatment. When such a strategy is discussed, it is important to notice that definition of oligometastases is not consensual both in terms of clinical presentation than on the biological basis. Does a specific biological background truly exist and are there markers that could predict for additional occult disease and its oligo or polymetastatic profile in individuals with demonstrated oligometastasis. This article provides a summary of the state of the art in this field and highlights some current areas of controversies...
June 2016: Bulletin du Cancer
Matthias F Häfner, Jürgen Debus
BACKGROUND: Multimodal treatment approaches are indispensable for patients with advanced-stage colorectal cancer. Radiotherapy has been established as essential part of perioperative concepts and was introduced as an option to face challenges such as local relapse or oligometastases. METHODS: A literature review was performed to summarize evidence and current standards of radiotherapeutic concepts in the treatment of colorectal cancer. RESULTS: For stage II/III rectal cancer, neoadjuvant radiotherapy is superior to adjuvant treatment...
June 2016: Visc Med
Jordan A Torok, Lin Gu, Daniel J Tandberg, Xiaofei Wang, David H Harpole, Chris R Kelsey, Joseph K Salama
BACKGROUND: Patients with limited metastases, oligometastases (OMs), might have improved outcomes compared with patients with widespread distant metastases (DMs). The incidence and behavior of OMs from non-small-cell lung cancer (NSCLC) need further characterization. PATIENTS AND METHODS: The medical records of patients who had undergone surgery for stage I-III NSCLC from 1995 to 2009 were retrospectively reviewed. All information pertaining to development of the first metastatic progression was recorded and analyzed...
July 5, 2016: Clinical Lung Cancer
Hao Bai, Jianlin Xu, Haitang Yang, Bo Jin, Yuqing Lou, Dan Wu, Baohui Han
INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients with 1-3 synchronous brain oligometastases, who were treated with stereotactic radiosurgery (SRS) or surgical resection as the primary treatment, were identified at Shanghai Chest Hospital...
2016: OncoTargets and Therapy
Kenichi Omae, Takao Hiraki, Hideo Gobara, Toshihiro Iguchi, Hiroyasu Fujiwara, Yusuke Matsui, Shinichi Toyooka, Takeshi Nagasaka, Susumu Kanazawa
PURPOSE: To conduct a retrospective evaluation of long-term survival after radiofrequency (RF) ablation for lung oligometastases from 5 types of primary lesions. MATERIALS AND METHODS: The study population consisted of 123 patients with lung oligometastases from colorectal cancer (CRC), non-small-cell lung cancer, hepatocellular carcinoma, esophageal cancer, and renal-cell carcinoma treated with RF ablation. Lung oligometastases were defined as 1-5 metastases confined to the lung while the primary cancer and other metastases were eradicated...
September 2016: Journal of Vascular and Interventional Radiology: JVIR
Rohann J M Correa, Joseph K Salama, Michael T Milano, David A Palma
Oligometastasis refers to a state of limited metastatic disease burden, in which surgical or ablative treatment to all known visible metastases holds promise to extend survival or even effect cure. Stereotactic body radiotherapy is a form of radiation treatment capable of delivering a high biologically effective dose of radiation in a highly conformal manner, with a favorable toxicity profile. Enthusiasm for oligometastasis ablation, however, should be counterbalanced against the limited supporting evidence...
July 2016: Cancer Journal
Lary A Robinson, Crystal J Jaing, Christine Pierce Campbell, Anthony Magliocco, Yin Xiong, Genevra Magliocco, James B Thissen, Scott Antonia
BACKGROUND: Although ∼20% of human cancers are caused by microorganisms, only suspicion exists for a microbial cause of lung cancer. Potential infectious agents were investigated in non-small cell lung cancer (NSCLC) and non-neoplastic lung. METHODS: Seventy NSCLC tumours (33 squamous cell carcinomas, 17 adenocarcinomas, 10 adenocarcinomas with lepidic spread, and 10 oligometastases) and 10 non-neoplastic lung specimens were evaluated for molecular evidence of microorganisms...
August 9, 2016: British Journal of Cancer
Tao Pan, Qian-Kun Xie, Ning Lv, Xi-Shan Li, Lu-Wen Mu, Pei-Hong Wu, Ming Zhao
Purpose To assess the effectiveness and safety of percutaneous computed tomography (CT)-guided radiofrequency ablation (RFA) for lymph node (LN) oligometastases from hepatocellular carcinoma (HCC). Materials and Methods This retrospective study was approved by the institutional ethics committee, and all patients provided written informed consent. From January 2004 to December 2013, 119 consecutive patients with HCC and LN oligometastases (115 men [mean age, 51.3 years; age range, 16-83 years] and four women [mean age, 38...
July 11, 2016: Radiology
Hania A Al-Hallaq, Steven Chmura, Joseph K Salama, Kathryn A Winter, Clifford G Robinson, Thomas M Pisansky, Virginia Borges, Jessica R Lowenstein, Susan McNulty, James M Galvin, David S Followill, Robert D Timmerman, Julia R White, Ying Xiao, Martha M Matuszak
INTRODUCTION: In 2014, the NRG Oncology Group initiated the first National Cancer Institute-sponsored, phase 1 clinical trial of stereotactic body radiation therapy (SBRT) for the treatment of multiple metastases in multiple organ sites (BR001; NCT02206334). The primary endpoint is to test the safety of SBRT for the treatment of 2 to 4 multiple lesions in several anatomic sites in a multi-institutional setting. Because of the technical challenges inherent to treating multiple lesions as their spatial separation decreases, we present the technical requirements for NRG-BR001 and the rationale for their selection...
May 20, 2016: Practical Radiation Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"